Annual report pursuant to Section 13 and 15(d)

Royalty and Commercial Payment Purchase Agreements - Agenus (Details)

v3.24.0.1
Royalty and Commercial Payment Purchase Agreements - Agenus (Details)
$ in Thousands
 1 Months Ended 12 Months Ended
Sep. 20, 2018
USD ($)
product
Nov. 30, 2020
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Agreements        
Payments of consideration under RPAs, AAAs and CPPAs     $ 14,650 $ 8,000
Short-term royalty and commercial payment receivables     14,215 $ 2,366
Royalty Purchase Agreement | Merck Immuno-Oncology Product | Agenus        
Agreements        
Amount of milestone payments earned under agreement   $ 10,000    
Agenus | Royalty Purchase Agreement        
Agreements        
Payments of consideration under RPAs, AAAs and CPPAs $ 15,000      
Acquisition of royalty and commercial payment receivables, Long-Term $ 15,000      
Amount of allowance for credit losses     $ 0  
Agenus | Royalty Purchase Agreement | Incyte Immuno-Oncology Assets        
Agreements        
Royalties entity has right to receive (as a percent) 33.00%      
Number of licensed products related to milestone and royalties | product 6      
Milestone payments entity has right to receive (as a percent) 10.00%      
Agenus | Royalty Purchase Agreement | Merck Immuno-Oncology Product        
Agreements        
Royalties entity has right to receive (as a percent) 33.00%      
Milestone payments entity has right to receive (as a percent) 10.00%      
Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones $ 59,500      
Amount of milestone payments earned under agreement   1,000    
Reduction in long-term royalty receivable balance due to receipt of payment   $ 1,000